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Abstract:  9 
The polyphenolic compound resveratrol has received significant attention due to its many 10 
pharmacological actions such as anti-cancer, anti-inflammatory, antioxidant and 11 
antimicrobial activities. However, poor solubility and stability are major impediments for 12 
resveratrol’s clinical effectiveness. In this work we have encapsulated resveratrol into soy 13 
protein isolate nanoparticles using a simple rotary evaporation technique. Resveratrol-loaded 14 
nanoparticles were around 100 nm in diameter and negatively charged. Nano-encapsulated 15 
resveratrol was found to be in amorphous form and showed more than two times higher 16 
solubility with significantly increased dissolution when compared to free resveratrol. Finally, 17 
an in-vitro NF-κB inhibition assay revealed that encapsulated resveratrol was stable and 18 
retained bioactivity. This new formulation of resveratrol has the potential to boost the clinical 19 
effectiveness of this drug and could be utilised for other poorly soluble hydrophobic drugs. 20 
 21 
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1. Introduction: 33 
More than half of the new chemical entities emerging from high throughput screening 34 
processes are poorly water-soluble, posing the challenge of improving their solubility, 35 
stability and hence their bioavailability.[1] Various pharmaceutical approaches have been 36 
explored to address this issue[2], such as particle size reduction[3], salt forms, co-solvents, 37 
and complexation, with limited success owing to drug degradation during mechanical forces, 38 
limited options to make the salt forms, or the complex procedures involved.[4-7] Recently, 39 
nanocomplexation with cyclodextrins and natural proteins such as zein, albumin, and whey 40 
protein has emerged as a novel and effective strategy to enhance the solubility of poorly 41 
soluble drugs and nutraceuticals, notably polyphenols.[8-10] However, many of these 42 
formulations suffer from complex loading techniques, use of large amounts of organic 43 
solvent, and are poorly characterised for the physical state of drug within these complexes. 44 
Therefore, there is an unmet need to develop a simple and effective encapsulation strategy, 45 
which not only improves the solubility of such poorly water-soluble drugs but also acts as a 46 
biodegradable drug carrier. 47 
 48 
Resveratrol chemically known as 3,5,4’-trihydroxystilbene, is a naturally occurring 49 
polyphenol found in red wine, grapes and peanuts.[11, 12] Resveratrol has been the 50 
subject of intensive research because of its multiple therapeutic effects, such as 51 
antioxidant, cardioprotective, anti-inflammatory and anticancer activity. However, 52 
resveratrol suffers from many pharmacokinetic limitations.[13-15] Resveratrol is 53 
classified as a biopharmaceutics classification system (BCS) class II drug, possessing 54 
poor aqueous solubility (~0.03 g/L) and high permeability.[16-18]. Resveratrol exists 55 
in two geometric isomers, cis- and trans-, with the latter being more abundant and 56 
biologically active[19-21]. But when resveratrol is exposed to light, conversion of 57 
trans-resveratrol to cis-resveratrol takes place via photoisomerization.[22, 23] When 58 
given orally the absorption of resveratrol in humans is high but its bioavailability is 59 
less than 1% due to extensive first pass metabolism in the liver[24, 25]. These poor 60 
pharmacokinetic properties coupled with poor solubility and dissolution could lead to 61 
lower Cmax and in turn lower bioavailability. Hence, improving resveratrol’s 62 
solubility and dissolution profile will ensure faster and complete absorption leading to 63 
higher Cmax and improved efficacy.  64 
 65 
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Attempts have been made to enhance resveratrol’s solubility by incorporating it into various 66 
nanocarriers, including liposomes[26, 27], cyclodextrins[28, 29], solid lipid 67 
nanoparticles[30], polymeric micelles[31] and polymeric nanoparticles[32]. However, these 68 
formulations suffer from drawbacks such as poor stability (e.g. liposomes[33]), complex 69 
procedures (polymer nanoparticles),[34] and high production costs (e.g. cyclodextrins and 70 
polymers[35, 36]). Recently, resveratrol was encapsulated into mesoporous silica 71 
nanoparticles (MSNs) which enhanced its solubility and improved anti-cancer targeting.[37] 72 
Despite substantial research into these novel inorganic nanocarriers, they are costly to 73 
produce, their biodegradability is still under investigation and they are not yet FDA approved 74 
for human use.[38-40] Hence, there is a pressing need for superior cost effective delivery 75 
carriers for nutraceuticals that needs to be delivered in high dose such as resveratrol.  76 
 77 
Soy protein isolate (SPI) derived from soybeans is one good candidate for drug solubility 78 
enhancement. SPI is used in the food industry due to its functional properties, non-toxic 79 
nature, low cost, easy availability and high nutritional values, and is a Generally Regarded As 80 
Safe (GRAS) compound and is US FDA approved for human use.[9, 41, 42] SPI has been 81 
used for solubility enhancement of curcumin, wherein curcumin was encapsulated in either 82 
unheated or heated (95 ºC) SPI to form nanocomplexes resulting in significant enhancement 83 
of solubility. SPI was heat treated in this study to impart hydrophobicity, as SPI is poorly 84 
soluble in water due to presence of hydrophobic amino acids.[41] However, encapsulation via 85 
heat treatment may not be suitable for many nutraceuticals, including resveratrol, and may 86 
adversely affect drug stability.    87 
 88 
In this study, we report a simple method for nanoencapsulation of resveratrol into SPI. We 89 
hypothesised that encapsulation of resveratrol using a rotavap technique would enhance its 90 
physicochemical properties including solubility and in-vitro dissolution, which will in turn 91 
improve its biological performance. Resveratrol-encapsulated SPI(SPI-RES) complexes were 92 
evaluated for size, zeta potential, drug loading, encapsulation efficiency, solubility, in vitro 93 
drug release and anti-inflammatory activity. The SPI-RES nanocomplexes improved 94 
resveratrol solubility and in vitro drug release profile, and hence these nanocomplexes could 95 
be easily administered orally as a nanosuspension and/or by formulation within tablets, 96 
thereby enhancing the overall applicability of resveratrol. 97 
 98 
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2. Materials and Methods: 99 
2.1 Materials: Soy Protein Isolate (SPI) and resveratrol were gift samples received from     100 
PRO-FAM
®
 974, Archer Daniels Midland, USA, and Candlewood Stars Inc., USA, 101 
respectively. 90% Ethanol was purchased from Merck, Germany, and Snakeskin
®
 dialysis 102 
tubing (MWCO 10 kDa) was from Thermoscientific, USA. All other solvents and excipients 103 
were of analytical grade and purchased from Sigma Aldrich, Australia. 104 
 105 
2.2 Characterization: Particle size and zeta potential were measured using a Malvern 106 
Zetasizer Nano-ZS. The nanocomplexes were then observed under a transmission electron 107 
microscope (TEM) by dispersing them in deionized water and placing on formvar heavy 108 
carbon-coated 300 mesh Cu grids. The samples were negatively stained with 2% uranyl 109 
acetate and then analysed at 80 kV using a JEOL 1010B TEM.[43] Wide angle X-ray 110 
diffractograms (XRD) were recorded on a Rigaku miniflex X-ray diffractometer with Fe 111 
filtered Co radiation (λ = 1.79 Å) in 2θ range 5-50. Fourier transform infrared (FTIR) spectra 112 
were recorded on a Thermo Nicolet Nexus 6700 FTIR spectrometer equipped with a diamond 113 
ATR (attenuated total reflection) crystal. For each spectrum, 128 scans and 4 cm
−1
 resolution 114 
was applied over the range of 400−4000 cm−1. Differential scanning calorimetry (DSC) 115 
measurements were performed using a Mettler Toledo TGA\DSC2 STAR system in 116 
temperature range of 50 – 600 °C with a heating rate of 5 °C/min in air flow. Resveratrol 117 
concentration was determined using a UV−Vis spectrophotometer (Varian Cary 50 Bio).  118 
 119 
2.3 Preparation of soy protein isolate – resveratrol complex: Soy protein isolate (SPI) was 120 
dispersed in deionized water at a concentration of 1 mg/mL and stirred for 30 min at 37 ºC. 121 
Resveratrol was dissolved in 90% ethanol (1 mg/mL). The ethanolic resveratrol solution was 122 
added drop wise to the SPI solution under stirring at 700 rpm to reach a polymer to drug w:w 123 
ratio of 9:1 and then stirred overnight at 37 ºC in the dark. After overnight stirring, ethanol 124 
was evaporated under reduced pressure in a rotary evaporator to obtain resveratrol-125 
encapsulated SPI (SPI-RES) complexes.[44] SPI nanoparticles were also prepared with the 126 
same method without resveratrol. The samples were then freeze dried and stored at RT in the 127 
dark before further use.   128 
 129 
2.4 Solubility studies: Saturated solubility was performed by placing 0.5 mg of resveratrol in 130 
0.5 mL of distilled water in an eppendorf tube under shaking for 48 hours at 37 ºC. After             131 
48 hours, the solution was centrifuged at 20,238 g for 10 min. The supernatant was collected 132 
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and the supernatant was analysed using a UV-Vis spectrophotometer at 305 nm. 133 
Resveratrol’s solubility in SPI-RES complexes was determined by dispersing complexes 134 
containing resveratrol equivalent to 0.5 mg and following the procedure used for pure 135 
resveratrol.  136 
 137 
2.5 In-vitro release studies: Cumulative release of resveratrol was performed under sink 138 
condition at 37 ºC in the dark with stirring (120 rpm) using phosphate buffer pH 1.2 139 
containing 2 μg/ml of pepsin solution (mimicking gastric fluid) for 2 h followed by phosphate 140 
buffer pH 7.4 containing 5 μg/ml pancreatin solution (25 mg/mL) and 0.5% tween-20 141 
(mimicking intestinal fluid) up to 24 h. 1 mg of resveratrol and 10 mg of SPI–RES complex 142 
equivalent to 1 mg resveratrol were dispersed individually in 5 mL of water. The drug and the 143 
mixture were transferred to dialysis tubing (MWCO 10 kDa), which was sealed and placed in 144 
a container with 45 mL of preheated phosphate buffer pH 1.2. At time intervals (0, 0.5, 1, 1.5 145 
and 2 h), aliquots of 1 mL were withdrawn, replaced with fresh buffer and measured for 146 
absorbance at 305 nm using a UV-Vis spectrophotometer. After 2 h, the dialysis tubes were 147 
placed in another container containing preheated 45 mL of phosphate buffer pH-7.4. At time 148 
intervals (1, 2, 4, 10 and 22 h), 1 mL aliquots were withdrawn and measured for absorbance 149 
at 305 nm.  150 
 151 
2.6 In-vitro anti-inflammatory assay:  152 
RAW 264.7 macrophage cells stably transfected with a GFP-inducing NF-κB reporter 153 
gene plasmid were seeded at 500,000 cells/well in 24 well plates in a fully-humidified 154 
incubator containing 5% CO2 and 95% air. To study the effect of resveratrol on 155 
inhibition of NF-κB, after overnight incubation cells were pre-treated with a range of 156 
concentrations of resveratrol in DMSO, and SPI-RES for 6 h and then 10 ng/ml of 157 
lipopolysaccharide (LPS) was added to activate NF-κB within the macrophages. After 158 
16 h incubation, cells were trypsinized, harvested as a single cell suspension and GFP 159 
expression due to NF-κB activation assessed using a CyAn ADP Analyzer (Beckman 160 
Coulter) and Flowjo 8.8.7v for analysis. To avoid any interference due to the 161 
nanoparticles independent of the drug, SPI was included in this assay as a negative 162 
control with and without addition of LPS.  163 
 164 
 165 
3. Result and Discussion: 166 
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3.1 Material Characterization: 167 
The particle size and zeta potential were measured for SPI, SPI nanoparticles and SPI-RES 168 
samples as shown in Table 1. The average size (Z-Avg) of SPI was in microns (~2 μm) but 169 
when SPI was formulated into nanoparticles using the rotavap technique, the size significantly 170 
decreased to 330 ± 27 nm while SPI – RES nanocomplexes were slightly larger in size              171 
(525 ± 33 nm) due to encapsulation of resveratrol within SPI nanoparticles. The intensity 172 
mean size of SPI, SPI nanoparticles and SPI-RES were 120 ± 12, 217 ± 10 and 122 ± 6 nm 173 
respectively as shown in Table 1. These intensity mean sizes are consistent with the TEM 174 
images for SPI (Fig. 1A), SPI nanoparticles (Fig. 1B) and SPI-RES (Fig. 1C). TEM images of 175 
SPI, SPI nanoparticles and SPI-RES indicate a spherical shape with a light core and dark shell 176 
due to negative staining. SPI, SPI nanoparticles and SPI-RES showed almost similar and 177 
highly negative zeta potential of around -35mV (Table 1). Soy protein isolate mainly consists 178 
of soy globulins, which possess negative charge in aqueous medium. Also resveratrol has a 179 
negative surface charge and thus the net charge of SPI-RES nanocomplexes was found to be 180 
negative. It is important to note that the poly dispersity index (PDI) of SPI was extremely high 181 
compared to SPI nanoparticles and SPI-RES (Fig. 1D-inset), which could be due to presence 182 
of impurities as SPI is derived from a natural source. Furthermore, the PDI of SPI 183 
nanoparticles and SPI‐RES after rotavap were both significantly lower than for SPI, which 184 
indicates an improvement in dispersity and affirms the advantage of our rotavap technique. 185 
 186 
 187 
 188 
 189 
 190 
 191 
 192 
 193 
 194 
 195 
 196 
 197 
Fig 1. Transmission electron microscopy (TEM) of (A) Soy protein isolate (SPI), (B) SPI 198 
nanoparticles and (C) resveratrol encapsulated SPI nanocomplex (SPI-RES, 199 
  
7 
 
nanoparticles shown by red arrows). (D) Particle size distribution and poly dispersity 200 
index (Inset) of SPI, SPI nanoparticles and SPI – RES nanocomplex. Statistics:  mean ± 201 
SD (n=3); ANOVA and Tukey’s post-hoc test; ****p < 0.0001. 202 
 203 
Table 1. Particle size and zeta measurements for SPI and SPI-RES samples 204 
Sr. 
No. 
Sample 
Z (Average) 
(nm) ± SD 
PDI 
Intensity mean 
size (nm) ± SD 
Zeta Potential 
(mV) ± SD 
1 SPI 2228 ± 101 1.00 ± 0.0 120 ± 12 -34.83 ± 1.35 
2 
SPI 
nanoparticles 
330 ± 26 0.42 ± 0.01 216  ± 10 -27.50 ± 1.74 
3 SPI–RES 525 ± 33 0.56 ± 0.03 122 ± 6 -35.76 ± 0.63 
 205 
To confirm the amorphous nature of resveratrol encapsulated in SPI, wide angle XRD 206 
(WXRD) was performed. As depicted in Fig. 2, pure resveratrol is a crystalline compound 207 
showing sharp diffractions in the 2θ range of 5−50°. The amorphous nature of SPI material is 208 
evidenced from the broad peak in the range of 2θ 15−25°. However, no obvious diffraction 209 
peaks originating from resveratrol can be observed in the SPI-RES nanocomplexes, 210 
suggesting the complete encapsulation of resveratrol in SPI and its amorphous nature within 211 
SPI.  212 
 213 
 214 
 215 
 216 
 217 
 218 
 219 
 220 
 221 
 222 
 223 
Fig 2. Wide angle x-ray diffraction (WXRD) patterns of Soy protein isolate (SPI), 224 
resveratrol (RES) and resveratrol encapsulated SPI nanocomplex (SPI-RES).  225 
 226 
Interaction of resveratrol with SPI was also analysed by conducting ATR-FTIR analysis in 227 
the range of 400−4000 cm−1 (Fig. 3A). We focused on the region of interest 500−2000 cm−1       228 
(Fig. 3B) to obtain more information about resveratrol encapsulation. The FTIR spectrum for 229 
resveratrol showed absorption bands of O–H stretching due the alcoholic group at 3191 cm-1 230 
(Fig. 3A). Moreover, FTIR spectra showed resveratrol peaks of C – C aromatic double bond 231 
stretching at 1604 cm
-1
, C–C olefinic stretching at 1581 cm-1, C=C stretching due to aromatic 232 
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ring at 1510 cm
-1
 and 1461 cm
-1
, C–O stretching vibration at 1383 cm-1, C–O stretching at 233 
1145 cm
-1
 and trans olefinic bands at 986 and 964 cm
-1
 (Fig. 3B).[45] The peaks relevant to 234 
resveratrol were also observed in the SPI-RES nano-complex confirming that resveratrol 235 
stays in its original chemical form within SPI.  236 
 237 
Fig. 3. ATR-FTIR spectra of Soy protein isolate (SPI), resveratrol (RES) and 238 
resveratrol encapsulated SPI nanocomplex (SPI-RES). (A) ART-FTIR (B) fingerprint 239 
region.  240 
 241 
DSC analysis was also conducted to further delineate the crystallinity of resveratrol in SPI-242 
RES. Pure resveratrol displays a sharp melting point peak at 266 ºC[10] as shown in Fig. 4. 243 
However, no such peak was observed for the SPI-RES sample indicating resveratrol’s 244 
amorphous state in the complex.  245 
 246 
 247 
 248 
 249 
 250 
 251 
 252 
 253 
 254 
 255 
 256 
 257 
Fig 4. Differential Scanning Colorimetry (DSC) profile of Soy protein isolate (SPI), 258 
resveratrol (RES) and resveratrol encapsulated SPI nanocomplex (SPI-RES).  259 
 260 
Solubility studies were performed to determine the effect of complexation on resveratrol 261 
solubility (Fig. 5). The solubility of the SPI-RES complex was 106.4 µg/mL, which was 2.3-262 
fold higher than pure resveratrol (46.7 µg/mL). In a previous study, resveratrol’s solubility 263 
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was determined to be 280 µg/mL.
9
 However, this higher solubility was result of the 264 
extraction protocol wherein acetonitrile (resveratrol has solubility of 5 mg/mL in acetonitrile) 265 
was used at a ratio of 9:1 leading to higher solubility.[9] Additionally, the solubility was 266 
measured via visual observation and therefore is only an approximation. Our aim of 267 
developing the rotavap technique was to successfully encapsulate resveratrol within SPI. This 268 
was achieved via a 2-step process. Firstly, resveratrol in ethanol and SPI in distilled water 269 
were mixed and stirred overnight to initiate the hydrophobic interaction between resveratrol 270 
and SPI. Secondly, during rotary evaporation due to reduced pressure ethanol is evaporated 271 
and, due to hydrophobic–hydrophobic interactions and capillary forces, resveratrol remains 272 
encapsulated within the hydrophobic region of SPI in an amorphous state. Therefore, we 273 
believe that our method provides a simple, clean and effective approach to complex 274 
resveratrol with the hydrophobic region of soy protein thereby enhancing solubility in a form 275 
which has the potential to be compressed into a tablet formulation.   276 
 277 
 278 
 279 
 280 
 281 
 282 
 283 
 284 
 285 
 286 
Fig 5. Saturated solubility studies of resveratrol (RES) and resveratrol encapsulated 287 
SPI nanocomplex (SPI-RES). Statistics: mean ± SD (n=3), t-test; ****p < 0.0001. 288 
 289 
It is widely accepted that drug solubility, dissolution and permeability are prerequisites to a 290 
successful and bioavailable dosage forms. Resveratrol is a BCS class-II nutraceutical and 291 
therefore it has poor solubility and very high permeability. Hence, in-vitro dissolution of 292 
resveratrol from SPI-RES nanocomplexes is another important parameter, which can predict 293 
its in-vivo bioavailability. The in-vitro release study was conducted at pH 1.2 and pH 7.4 294 
mimicking the gastric and intestinal environments, respectively (Fig. 6). Resveratrol showed 295 
16.2 ± 0.16 % release in pH 1.2 whereas it further released 36.9 ± 0.66 % in pH 7.4. It is 296 
interesting to note that the cumulative release of pure resveratrol is saturated around 50%, 297 
even in the presence of surfactant, displaying limited dissolution which could lead to lower 298 
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Cmax than desired resulting in poor efficacy in-vivo. On the other hand, SPI-RES complex 299 
showed significantly higher release of resveratrol of 59.9 ± 2.19 % in pH 1.2 while it further 300 
released 29.2 ± 2.49 % of resveratrol in pH 7.4 demonstrating the advantage of SPI-RES 301 
nanocomplex. This faster release of resveratrol from SPI-RES complex in the dissolution 302 
medium can be attributed to its improved solubility from the SPI-RES nanocomplex. 303 
 304 
 305 
 306 
 307 
 308 
 309 
 310 
 311 
 312 
Fig. 6. In-vitro release profile of pure resveratrol (RES) and resveratrol encapsulated 313 
SPI nanocomplex (SPI-RES). Mean ± SD (n=3). 314 
 315 
Apart from poor solubility and rapid pharmacokinetics, resveratrol also suffers from poor 316 
stability in solution hampering its long-term storage stability. As our nanocomplexation 317 
involves use of an organic solvent, a high rotary evaporator and freeze drying, it was 318 
important to compare the bioactivity of SPI-RES nanocomplexes with freshly prepared 319 
solution and suspension. Nuclear factor kappa B (NF-κB) plays an important role in human 320 
disorders such as inflammation and cancer and it is a potential target for prevention of cancer 321 
in chronic inflammation. Thus, in order to assess the bioactivity and stability of resveratrol 322 
within SPI-RES nanocomplexes, we used an LPS-dependent NF-κB activation bioassay by 323 
measuring GFP expression using RAW 264.7 NF-kB reporter cells. These cells express GFP 324 
in response to exposure to LPS and we measured the ability of pre-treatment with resveratrol 325 
to inhibit GFP induction by LPS. As shown in Fig. 7, at lower concentrations resveratrol 326 
solutions and resveratrol suspensions showed higher significant % GFP reduction compared 327 
to SPI-RES. However, at higher concentrations of 20 μg/ml and 30 μg/ml SPI-RES showed a 328 
non-significant trend toward a greater reduction in GFP as compared to free drug. It is 329 
important to note that SPI on its own induced GFP (possibly due to low level LPS 330 
  
11 
 
contamination), which could underestimate the ability of our SPI-RES formulation to 331 
decrease NF-κB. Nevertheless, this test confirms that the resveratrol released from SPI-RES 332 
nanocomplex is still as bioactive as pure solutions or suspensions of resveratrol. 333 
 334 
 335 
 336 
 337 
 338 
 339 
 340 
 341 
 342 
 343 
 344 
 345 
 346 
Fig. 7. In-vitro bioactivity assay measuring inhibition by different formulations of 347 
resveratrol of the NF-κB activation by LPS in RAW264.7 macrophages transfected with 348 
a NF-κB GFP reporter plasmid. Statistics: mean ± SD (n=3), ANOVA and Tukey’s post-349 
hoc test. 350 
 351 
Conclusion: 352 
Resveratrol has multiple therapeutic effects including antioxidant, cardioprotective, anti-353 
inflammatory and anticancer activity, however these are limited by the drugs poor aqueous 354 
solubility and stability. We hypothesized that nanocomplexing resveratrol with soy protein 355 
isolate would improve its solubility and dissolution, which consequently will improve its 356 
bioavailability. A complex between soy protein isolate and resveratrol (RES) was realised via 357 
a simple, yet effective, rotavap technique and particles were thoroughly characterized for 358 
encapsulation and crystallinity of the drug. SPI has been previously used to encapsulate 359 
hydrophobic nutraceuticals such as curcumin and resveratrol however, the encapsulation 360 
method involved use of heat (95
o
C) and a toxic solvent acetonitrile to prepare 361 
nanocomplexes
9,38
. Therefore, the published method could be unsuitable for heat sensitive 362 
nutraceuticals and remaining traces of organic solvent could limit its use in clinical setting 363 
due to toxicity. Thus our facile method provides a simple and innovative approach to improve 364 
the physicochemical properties of resveratrol. We found that resveratrol was in an amorphous 365 
state within these nanocomplexes, confirming successful encapsulation. Solubility studies 366 
showed a two-fold increase in aqueous solubility of encapsulated resveratrol, and the SPI-367 
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RES complexes showed a significantly higher and faster drug release than the free drug. 368 
Finally, an in-vitro NF-kB assay revealed that resveratrol is stable and bioactive within the 369 
SPI-nanocomplex providing further evidence of superior formulation. Future work will focus 370 
on delivery of resveratrol and other similar hydrophobic drugs in the gastrointestinal tract by 371 
using surface modification and crosslinking of the SPI-nanoparticles to enhance survival in 372 
the upper tract and delivery to the required site of action. We will also assess formulations 373 
with and without surface modifications in-vivo for improvements in pharmacokinetics and 374 
anti-inflammatory activity. Together our findings demonstrate that the method of 375 
encapsulation in soy protein we have described constitutes a feasible approach to deliver 376 
resveratrol and other hydrophobic drugs in effective pharmaceutical dosage forms. 377 
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